Sandostatin LAR Articles
Novartis drug slows 69% of GI tumors
26 January 2009
77% of patients on RAD001 achieve stable pancreatic NET tumors
22 September 2008
Octreotide implant sees 6-month efficacy
10 December 2007
Expanded use for Novartis' Sandostatin LAR in UK
5 July 2004
Novartis' Sandostatin LAR OKed in Japan
3 May 2004
Novartis Compares Growth Hormone Therapies
17 June 1999
Novartis' Sandostatin LAR Depot Approved By FDA
2 December 1998
Novartis Files NDA For Sandostatin LAR
4 June 1998
Novartis Launches Sandostatin LAR In First Market
18 December 1997
Showing 1-15 of 15 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
